A Phase 2b Randomized, Double-blind, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Crohn’s Disease

Project: Research

HREC Reference Number: HREC/89328/MH-2022
SSA Reference Number: SSA/89328/MonH-2023-365209(v1)
Monash Health Local Reference: RES-23-0000-241X

Status	Active
Effective start/end date	15/05/23 → 14/05/28

Project Details